Arguello et al. [48] have also reported positive results with an IDS transport vehicle (DNL 310) utilizing transferrin receptor-mediated transcytosis in MPS II mice: reduced levels of peripheral and CNS GAGs were noted along with improvements in auricular, skeletal, and neurobehavioural abnormalities, although the dose-response relationship between these effects and DNL 310 have apparently not yet been examined. This evidence concerns the gene TFRC and mucopolysaccharidosis type 2.